ULTOMIRIS

उत्पाद अवलोकन

About ULTOMIRIS

ULTOMIRIS is a medication containing the active ingredient ravulizumab, classified as Complement Inhibitor. Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older.
• Use only as directed on the product label or by a healthcare professional.
• Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

ravulizumab, the active ingredient in ULTOMIRIS, belongs to the Complement Inhibitor class. 1 INDICATIONS AND USAGE ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking ULTOMIRIS. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use ULTOMIRIS for extended periods without medical advice.